FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vachington	D C	20540
Vashington,	D.C.	20549

STATEMENT (	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

	OMB APPROVAL					
	OMB Number: 3235-0287					
l	Estimated average burden					
l	hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HERSHBERG ROBERT  (Last) (First) (Middle)				RI IN	RECURSION PHARMACEUTICALS, INC. [ RXRX ]								(Che	S. Relationship of Reporting (Check all applicable)  X Director Officer (give title below)			10% Ov Other (s below)	vner	
		TCALS		04/	/15/2	2021													
(Street) SALT LAKE CITY UT 84101  (City) (State) (Zip)				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
			n-Deriv	ative	e Se	curitie	s Ad	cqu	ired,	Disp	osed o	of, or	Bene	ficially	Owned				
Security (Inst	tr. 3)		Date		ear)	Execution if any	n Date	e,	Transac Code (I		4. Securi Dispose 5)	ities Ac d Of (D)	quired (Instr.	(A) or 3, 4 and	Securities Beneficia Owned F	s lly ollowing	Form: Direct (D) or Indirect lowing (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
								Code	v	Amount (A) or (D) Pri		Price	Transacti	ion(s)			(Instr. 4)		
Stock <sup>(1)</sup>			04/10	04/16/2021					A		6,250 <sup>(2)</sup> A S		\$0.00	6,250			D		
															Owned				
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution D if any	ate, T	4. Transaction Code (Instr. 8)		of		Exp	<b>Expiration Date</b>		of Secur r) Underlyi Derivativ		curities rlying ative Security		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficial Owned Following Reported	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
			c	ode	v	(A)	(D)					Title	or Ni	umber					
\$18	04/15/2021			A		12,500			(3)	04	/14/2031			2,500	\$0.00	12,50	0	D	
\$2.22									(4)	03	3/19/2030			25,000		525,00	00	D	
	(FCURSION IO GRANDIO G	(First) CURSION PHARMACEUT O GRANDE STREET  AKE UT  (State)  Tal Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  \$18 04/15/2021	(First) (Middle) CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  (State) (Zip)  Table I - Note Security (Instr. 3)  2. Stock(1)  Table II -  2. Conversion Date (Month/Day/Year) Price of Derivative Security  \$18 04/15/2021	(First) (Middle) CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  (State) (Zip)  Table I - Non-Deriv Security (Instr. 3)  2. Trans Date (Month/) Table II - Deriva (e.g., p  2. Conversion or Exercise Price of Derivative Security  8 18 04/15/2021	(First) (Middle)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  (State) (Zip)  Table I - Non-Derivativ  Security (Instr. 3)  2. Transaction Date (Month/Day/Year) Or Exercise Price of Derivative Security Security  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  2. Table II - Derivative (e.g., puts, if any (Month/Day/Year)  (Month/Day/Year)  Code (III)  Code (III)	(First) (Middle)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Table III - Derivative Security (e.g., puts, call fany (Month/Day/Year)  2. Table III - Derivative Security (instr. 3)  2. Transaction Date (instr. 3)  A Deemed Execution Date, if any (Month/Day/Year)  Security (Month/Day/Year)  A Code V  \$18 04/15/2021  A	(First) (Middle)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  Table I - Non-Derivative Securitie Security (Instr. 3)  2. Transaction Date (Month/Day/Year) Table II - Derivative Securities (e.g., puts, calls, warrong or Exercise Price of Derivative Security Security  2. Conversion or Exercise Price of Derivative Security Security  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  3. Transaction Date (Month/Day/Year) (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrong farrong price of Derivative Security  Code (Instr. 8)  Code (Instr. 8)  Code (Na)  Code (Na)  Code (Na)  Code (Na)  Code (Na)  A 12,500	RECURSION FINC. [RXRX]	RECURSION PHA- INC. [RXRX]  (First) (Middle)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  (State) (Zip)  Table I - Non-Derivative Securities Acquire (Month/Day/Year)  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, or or Exercise Price of Derivative Security  (Month/Day/Year)  2. Conversion or Exercise Price of Derivative Security  (Month/Day/Year)  3. Transaction Date (e.g., puts, calls, warrants, or of or Execution Date, if any (Month/Day/Year)  (Month/Day/Year)  A 12,500  Date (Month/Day/Year)  Code V (A) (D) Date Execution Date (Month/Day/Year)  Sala 04/15/2021  A 12,500	RECURSION PHARM   INC. [RXRX]	Code   V   Code   C	RECURSION PHARMACEUTIC INC. [RXRX]  3. Date of Earliest Transaction (Month/Day/Year) 04/15/2021  4. If Amendment, Date of Original Filed (Month/Day/Year) 24. Deemed Execution Date (Instr. 3)  5. Transaction Date (Month/Day/Year)  Code V Amount Code (Instr. 3)  2. Transaction Date (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converting Code (Instr. 8)  2. Transaction Date (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converting Code (Instr. 8)  2. Transaction Date (Instr. 3)  Code V Amount Code (Instr. 8)  Code V (A) (D) Date Expiration Date (Month/Day/Year)  Security (Instr. 3)  A Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, converting Code (Instr. 8)  Code V (A) (D) Date Expiration Date (Month/Day/Year)  Salvation (Month/Day/Year)  A Code V (A) (D) Date Expiration Date (Month/Day/Year)  Code V (A) (D) Date Expiration Date (Month/Day/Year)  Salvation (Month/Day/Year)  A 12,500 (3) 04/14/2031	RECURSION PHARMACEUTICALS   INC. [RXRX]	Code   V   Amount   Code (Instr.   Amount   Code (Instr.   Amount   Code (Instr.   Amount   Code (Instr.   Co	RECURSION PHARMACEUTICALS, INC. [RXRX]    CURSION PHARMACEUTICALS   S.   INC.   RXRX	RECURSION PHARMACEUTICALS, (Check all applications)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE  UT  84101  Security (Instr. 3)  2. Transaction and the following and the fo	HBERG ROBERT  (First) (Middle)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  2. Transaction (Month/Day/Year) (Month/Day/Year)  2. Transaction (Month/Day/Year) (Month/Day/Year)  2. Transaction (Month/Day/Year) (Month/Day/Year)  2. Transaction (Month/Day/Year) (Month/Day/Year)  3. Transaction (Month/Day/Year) (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  3. Transaction (Month/Day/Year) (Month/Day/Year)  4. Securities Acquired (A) or Escurities Acquired (A) or Disposed of (B) or Disposed of (C) (D) (Inst. S. 4 and S) (Inst. S. 4 and S) (Inst. S) (	HBERG ROBERT  (First) (Middle)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE UT 84101  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year)  (Month/Day/Year)  Date (Month/Day/Year)  2. Transaction (Month/Day/Year)  2. Transaction (Month/Day/Year)  (Month/Day/Year)  2. Transaction (Month/Day/Year)  (Month/Day/Year)  2. Transaction (Month/Day/Year)  (Month/Day/Year)  2. Transaction (Month/Day/Year)  2. Transaction (Month/Day/Year)  (Month/Day/Year)  3. Transaction (Month/Day/Year)  (Month/Day/Year)  3. Transaction (Month/Day/Year)  (Month/Day/Year)  3. Transaction (Month/Day/Year)  (Month/Day/Year)  3. Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction (Month/Day/Year)  (Month/Day/Year)  3. Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction (Month/Day/Year)  (Month/Day/Year)  3. Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction (Month/Day/Year)  (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction (Month/Day/Year)  A G. Securities Acquired A, Or or Beneficially Owned (Inst. 3, and 4)  3. Transaction (Month/Day/Year)  (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction (Month/Day/Year)  4. If Amendment, Date of Earlies (Transaction) (Month/Day/Year)  4. If Amendment, Date of Earlies (Transaction) (Month/Day/Year)  (Month/Day/Year)  4. If Amendment, Date of Earlies (Transaction) (Month/Day/Year)  4. If Amendment, Date of Earlies (Month/Day/Year)  4. If Amendment, Date of Earlies (Transaction) (Month/Day/Year)  5. Amount of Securities (Souther Associati	RECURSION PHARMACEUTICALS, (Middle)  CURSION PHARMACEUTICALS O GRANDE STREET  AKE  UT  84101  Security (Instr. 3)  AKE  UT  84101  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Execution Date (Month/Day/Year)  (Month/Day/Year)  A

## **Explanation of Responses:**

- 1. Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock.
- 2. The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with all such shares being received on the earlier of April 16, 2022 or the Issuer's first annual meeting of stockholders. In the event the Reporting Person ceases to be a service provider to the Issuer, the unvested RSUs will be cancelled by the Issuer.
- 3. The option becomes exercisable upon the earlier of April 15, 2022 or the date of the Issuer's first annual meeting of stockholders.
- 4. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 16, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.

## Remarks:

/s/ Nathan Hatfield, attorney-in-<u>fact</u>

\*\* Signature of Reporting Person

04/19/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of Recursion Pharmaceuticals, Inc. (the "Company"), hereby constitutes and appoints Louisa Daniels, Nathan Hatfield and Jonathan Golightly, each, the undersigned's true and lawful attorney-in-fact to:

- (1) complete and execute Forms ID, 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- (2) do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 6, 2021.

/	s/ Robert Hershberg
Signat	ure
	Robert Hershberg
 Print	